ARQT Arcutis Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1787306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.0%
TTM net income YoY167.5%
TTM EPS YoY164.7%
Revenue 3-yr CAGR118.1%
Net income 3-yr CAGR—
Margins
Gross margin91.2%
Operating margin6.9%
Net margin5.9%
FCF margin11.7%
EBITDA margin—
Returns
ROE14.9%
ROA6.7%
ROIC (approx.)10.3%
Asset turnover1.14x
Leverage & solvency
Liabilities / assets53.5%
Debt / equity0.45x
Current ratio2.92x
Interest coverage2.56x
Cash quality & payout
Operating cash flow / net income2.00x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $376.07M | $196.54M |
| Cost of revenue | $36.70M | $19.13M |
| Gross profit | $339.38M | $177.41M |
| R&D expense | $77.05M | $76.42M |
| SG&A expense | $274.55M | $229.39M |
| Operating income | -$12.23M | -$128.40M |
| Interest expense | $12.08M | $27.17M |
| Pretax income | -$8.24M | -$130.37M |
| Income tax | $1.17M | $647,000 |
| Net income | -$16.14M | -$140.04M |
| EBITDA | -$11.53M | -$127.80M |
| EPS (basic) | -0.13 | -1.16 |
| EPS (diluted) | -0.13 | -1.16 |
| Weighted avg. shares (diluted) | 127.23M | 120.96M |
| Balance sheet | ||
| Cash & equivalents | $42.91M | $71.95M |
| Short-term investments | $178.07M | $156.62M |
| Receivables | $146.23M | $73.07M |
| Inventory | $22.63M | $14.53M |
| Current assets | $411.23M | $335.82M |
| PP&E, net | $1.04M | $1.04M |
| Intangibles | $14.81M | $9.48M |
| Total assets | $432.97M | $348.89M |
| Current liabilities | $129.84M | $81.01M |
| Short-term debt | $1.00M | $0 |
| Long-term debt | $107.96M | $107.20M |
| Total debt | $108.96M | $107.20M |
| Total liabilities | $243.49M | $191.35M |
| Shareholders' equity | $189.48M | $157.54M |
| Net debt | $66.05M | $35.25M |
| Shares outstanding | 123.33M | 117.85M |
| Cash flow statement | ||
| Operating cash flow | -$5.62M | -$112.16M |
| Capital expenditure | $686,000 | $143,000 |
| Free cash flow | -$6.31M | -$112.30M |
| Investing cash flow | -$30.25M | $28.82M |
| Financing cash flow | $6.97M | $66.20M |
| Depreciation & amortization | $700,000 | $600,000 |
| Stock-based compensation | $40.36M | $41.73M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.